Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation

Journal of Heart and Lung Transplantation

Volumn 23, Issue 11, 2004, Pages 1277-1282

  Devyatko, Elena ^a,b   Zuckermann, Andreas ^a   Ruzicka, Margot ^a   Bohdjalian, Arthur ^a   Wieselthaler, Georg ^a   Rödler, Susanne ^a   Wolner, Ernst ^a   Grimm, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Dermatology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; VALGANCICLOVIR;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; MALE; NAUSEA; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED;

EID: 8144231380     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.08.034     Document Type: Article

References (34)

1. Fishman J.A., Rubin R.H. Infection in organ transplant recipients. N Engl J Med. 338:1998;1741-1751
2. Sia I.G., Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev. 13:2000;83-121
3. Rubin R.H. Cytomegalovirus disease and allograft loss after organ transplantation. [editorial; comment] Clin Infect Dis. 26:1998;871-873
4. Koskinen P.K., Kallio E.A., Tikkanen J.M., et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis. 1:1999;115-126
5. Valantine H.A. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transpl Infect Dis. 1:(Suppl1):1999;25-30
6. Bostom A.D., Brown R.S. Jr, Chavers B.M., et al. Prevention of post-transplant cardiovascular disease - report and recommendation of ad hoc group. Am J Transplant. 2:2002;491-500
7. Akposso K., Rondeau E., Haymann J.P., et al. Long-term prognosis of renal transplantation after pre-emptive treatment of cytomegalovirus infection. Transplantation. 63:1997;974-976
8. Grossi P., Minoli L., Percivalle E., et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation. 59:1995;847-851
9. Patel R., Paya C.V. Infection in solid-organ transplant recipients. Clin Microbiol Rev. 10:1997;86-124
10. Patel R., Paya C.V. Cytomegalovirus infection and disease in solid organ transplant recipients. Bowden R.A., Ljungman P., Paya C.V. Transplant infections. 1998;229-244 Lippincott-Raven Publishers, Philadelphia
11. Couchoud C., Cucherat M., Haugh M., Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation a meta-analysis. Transplantation. 65:1998;641-647
12. Baldanti F., Simoncini L., Saracini A., et al. Ganciclovir resistance as a result of oral ganciclovir in heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation. 66:1998;324-329
13. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet. 356:2000;645-649
14. Drew W.L., Paya C.V., Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant. 1:2001;307-312
15. Griffiths P.D. The 2001 Garrod lecture. The treatment of cytomegalovirus infection. J Antimicrob Chemother. 49:2002;243-253
16. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 56:1998;115-146
17. Gane E., Saliba F., Valdecasas G., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients results of multicenter, multinational clinical trial. Lancet. 350:1997;1729-1733
18. Brown F., Banken L., Saywell K., Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 37:1999;167-176
19. Jung D., Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 39:1999;800-804
20. Martin D.F., Sierra-Madero J., Walmsley S., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 346:2002;1119-1126
21. Pescovitz M.D., Rabkin J., Merion R.M., et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 44:2000;2811-2815
22. Pescovitz M.D. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpl Infect Dis. 1:(Suppl1):1999;31-34
23. Paya CV. A randomised, double-blind, double-dummy, active-comparator, controlled, multicenter study of the efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of CMV disease in 372 D+/R- heart, liver and kidney recipients. On behalf of the Valganciclovir Solid Organ Transplant Study Group Mayo Clinic, Rochester, Minnesota; unpublished data
24. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 32:2001;742-751
25. Basgoz N., Preiksaitis J. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am. 9:1995;901-923
26. Cooper D.K., Novitzky D., Schlegel V., et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 10:1991;656-662
27. Icenogle T.B., Peterson E., Ray G., et al. DHPG effectively treats CMV infection in heart and heart-lung transplant patients a preliminary report. J Heart Transplant. 6:1987;199-203
28. Valantine H.A., Gao S.-Z., Menon S.G., et al. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis. A post-hoc analysis of randomised, placebo-controlled study. Circulation. 100:1999;61-66
29. Patel R., Snydman D.R., Rubin R.H., et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation. 61:1996;1279-1289
30. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 340:1999;1462-1470
31. Wreghitt T.G., Abel S.J., McNeil K., et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int. 12:1999;254-260
32. Paya C.V., Wilson J.A., Espy M.J., et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients a randomized, placebo-controlled trial. J Infect Dis. 185:2002;854-860
33. Hart G.D., Paya C.V. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 11:2001;73-81
34. Boeckh M., Boivin G. Quantitation of cytomegalovirus methodologic aspects and clinical application. Clin Microbiol Rev. 11:1998;533-554